These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
362 related articles for article (PubMed ID: 33331183)
21. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis. Siddiqui MK; Khurana IS; Budhia S; Hettle R; Harty G; Wong SL Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804 [TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan K; Rieckmann P; Comi G; Dangond F; Adeniji AK; Vermersch P Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107 [TBL] [Abstract][Full Text] [Related]
23. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study. Alroughani R; Al-Hashel J; Ahmed SF Clin Neurol Neurosurg; 2024 May; 240():108249. PubMed ID: 38513425 [TBL] [Abstract][Full Text] [Related]
24. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study. Rauma I; Viitala M; Kuusisto H; Atula S; Sipilä JOT; Ryytty M; Soilu-Hänninen M; Järvinen E Mult Scler Relat Disord; 2022 May; 61():103755. PubMed ID: 35483129 [TBL] [Abstract][Full Text] [Related]
25. Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon. Matni M; Yamout B; Koussa S; Khamis C; Fleifel L; Sharifi S; Mohamed O Mult Scler Relat Disord; 2022 Nov; 67():104169. PubMed ID: 36150262 [TBL] [Abstract][Full Text] [Related]
27. Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: The CLARENCE study. Brownlee W; Amin A; Ashton L; Herbert A Mult Scler Relat Disord; 2023 Nov; 79():104951. PubMed ID: 37639781 [TBL] [Abstract][Full Text] [Related]
28. Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. Cree BAC; Bowen JD; Hartung HP; Vermersch P; Hughes B; Damian D; Hyvert Y; Dangond F; Galazka A; Grosso M; Jones DL; Leist TP Mult Scler Relat Disord; 2021 Apr; 49():102695. PubMed ID: 33578191 [TBL] [Abstract][Full Text] [Related]
29. CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis. Miravalle AA; Katz J; Robertson D; Hayward B; Harlow DE; Lebson LA; Sloane JA; Bass AD; Fox EJ Neurodegener Dis Manag; 2021 Apr; 11(2):99-111. PubMed ID: 33517769 [TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal. Pinheiro B; Guerreiro R; Costa J; Miguel LS J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777 [No Abstract] [Full Text] [Related]
33. Economic Evaluation of Cladribine Tablets in Patients With High Disease Activity-Relapsing-Remitting Multiple Sclerosis in the Kingdom of Saudi Arabia. Bohlega S; Elboghdady A; Al-Johani A; Mahajan K; Mughari MK; Al-Saqa'aby M; Mohamed O; Alarieh R; Al Malik Y Value Health Reg Issues; 2021 Sep; 25():189-195. PubMed ID: 34425468 [TBL] [Abstract][Full Text] [Related]
35. Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study. Gorrod HB; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL Value Health; 2019 Jul; 22(7):772-776. PubMed ID: 31277823 [TBL] [Abstract][Full Text] [Related]
36. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary. Stefano N; Sormani MP; Giovannoni G; Rammohan K; Leist TP; Coyle PK; Dangond F; Alexandri N; Galazka A Neurodegener Dis Manag; 2022 Dec; 12(6):303-310. PubMed ID: 36017797 [TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Giovannoni G; Boyko A; Correale J; Edan G; Freedman MS; Montalban X; Rammohan K; Stefoski D; Yamout B; Leist T; Aydemir A; Borsi L; Verdun di Cantogno E Mult Scler; 2023 May; 29(6):719-730. PubMed ID: 37012898 [TBL] [Abstract][Full Text] [Related]
38. Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis. Piasecka-Stryczyńska K; Kaczyński Ł; Rolka M; Homa M; Staśkiewicz W; Paczwa P; Wójcik R; Kaczor MP; Rejdak K Neurol Neurochir Pol; 2022; 56(6):480-489. PubMed ID: 36421066 [TBL] [Abstract][Full Text] [Related]
39. Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy. Lizak N; Hodgkinson S; Butler E; Lechner-Scott J; Slee M; McCombe PA; Shaw C; Skibina O; Vucic S; Shuey N; Barnett MH; Parratt J; Butzkueven H; Jack D; Fabris J; Kalincik T Mult Scler; 2021 Mar; 27(3):465-474. PubMed ID: 32530363 [TBL] [Abstract][Full Text] [Related]
40. Effect of smoking on disease activity in multiple sclerosis patients treated with dimethyl fumarate or fingolimod. Tanaka E; Watanabe M; Fukumoto S; Masaki K; Yamasaki R; Matsushita T; Isobe N Mult Scler Relat Disord; 2023 Feb; 70():104513. PubMed ID: 36689892 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]